A Double-blinded, Randomized Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of N1, N3-bis-(2-Mercaptoethyl) Isophthalamide (NBMI) in the Reduction of Mercury Levels, in Subjects Exposed to Mercury in Colombia

NBMI (N1, N3-Bis-(2-Mercaptoethyl) Isophthalamide) is a new metal chelator drug proposed as an alternative to the current chelators, and it is widely different; compared to the current chelators, consisting of two cysteamine molecules coupled to a single molecule of dicarboxybenzoate. It is used as a chelating agent and has the designation of an orphan drug, in the EU and USA; in the EU it is used for the treatment of mercury toxicity. It is freely soluble in solutions of dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and sodium hydroxide diluted NaOH, slightly soluble in methanol and acetone, and insoluble in water. Pre-clinical data indicates low to no toxicity, and that it reduces the toxicity associated with acute exposure to Hg2+.
No other chelator has been reported to prevent acute mercury toxicity with only one exposure to the chelator. It has the ability to penetrate cell membranes and cross the blood-brain barrier and chelate Hg2+ in a complex that eliminates the availability of Hg2+ and essentially eliminates toxic effects. The antioxidant properties of NBMI could also reduce the toxicity levels of hydroxyl free radicals immediately, upon entering cells suffering from oxidative stress. It is possible that the combined chelation of Hg2+ and the elimination of hydroxyl free radicals contribute significantly to the protective effects observed with the NBMI.
Previous clinical studies conducted in subjects of the Phase I and Phase II a studies conducted, did not show significant adverse events in patients intoxicated with mercury, all patients who received the study medication have tolerated it well, with only mild or moderate adverse events reported; None of these were considered related to the pharmacological treatment of the study. In addition, there is no potential identified with safety problems in laboratory tests, or vital signs evaluations.
The purpose of this Controlled Single-Center Double-Blind Crossover Clinical Trial Phase II b is to determine the efficacy, safety and tolerability of a 14 day 600mg / day of NBMI (N1, N2-bis-2-mercaptoethyl isophthalamide) Treatment, in the reduction of urinary mercury levels versus placebo, in accidentally exposed subjects to mercury in Colombia.

Start Date22 Nov 2023

Sponsor / Collaborator

EmeraMed Ltd.

NCT04092205 / CompletedPhase 2

EMERA007 - An Open Label, Active-treatment Controlled, Phase 2a Pilot Study to Explore Safety and Efficacy of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation

A pilot study to explore safety and efficacy of NBMI treatment in patients with Beta Thalassemia Major requiring iron chelation
Investigational product: NBMI (N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide
Indication: Beta Thalassemia Major

Start Date21 Nov 2019

Sponsor / Collaborator

EmeraMed Ltd.

NCT04184063 / CompletedPhase 2

A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to Explore Efficacy and Safety of NBMI Treatment in Patients With Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA)

In total 20 subjects will be enrolled at one participating site -UMC Ljubljana. The 20 subjects will be treated with placebo and NBMI 300 mg in a cross-over design. In case of subject drop-outs, additional subjects may be enrolled as decided by the Sponsor, to allow for expected number of evaluable subjects in each group.

Start Date16 Sep 2019

Sponsor / Collaborator

EmeraMed Ltd.

100 Clinical Results associated with Emeramide

100 Translational Medicine associated with Emeramide

100 Patents (Medical) associated with Emeramide

242

Literatures (Medical) associated with Emeramide

31 Dec 2024·Epigenetics

One-carbon metabolism nutrients impact the interplay between DNA methylation and gene expression in liver, enhancing protein synthesis in Atlantic salmon

Article

Author: Saito, Takaya ; Espe, Marit ; Bock, Christoph ; Adam, Anne-Catrin ; Skjaerven, Kaja H ; Fernandes, Jorge M O ; Thomsen, Tårn H ; Vikeså, Vibeke

Supplementation of one-carbon (1C) metabolism micronutrients, which include B-vitamins and methionine, is essential for the healthy growth and development of Atlantic salmon (Salmo salar). However, the recent shift towards non-fish meal diets in salmon aquaculture has led to the need for reassessments of recommended micronutrient levels. Despite the importance of 1C metabolism in growth performance and various cellular regulations, the molecular mechanisms affected by these dietary alterations are less understood. To investigate the molecular effect of 1C nutrients, we analysed gene expression and DNA methylation using two types of omics data: RNA sequencing (RNA-seq) and reduced-representation bisulphite sequencing (RRBS). We collected liver samples at the end of a feeding trial that lasted 220 days through the smoltification stage, where fish were fed three different levels of four key 1C nutrients: methionine, vitamin B6, B9, and B12. Our results indicate that the dosage of 1C nutrients significantly impacts genetic and epigenetic regulations in the liver of Atlantic salmon, particularly in biological pathways related to protein synthesis. The interplay between DNA methylation and gene expression in these pathways may play an important role in the mechanisms underlying growth performance affected by 1C metabolism.

01 Nov 2024·Otolaryngology–Head and Neck Surgery

Outcomes and Complications of Pediatric Eustachian Tube Dilation Surgery

Article

Author: Mukerji, Shraddha ; Liu, Yi‐Chun Carol ; Rochat, Ryan ; Hosek, Katherine ; Rosas Herrera, Ana Maria

AbstractObjectiveTo determine whether balloon dilation of Eustachian tube (BDET) improves postoperative audiology and quality of life scores in children with chronic Eustachian tube dysfunction.Study DesignRetrospective study.SettingTertiary care pediatric center.MethodsEligible participants were patients 8 years or older, with a history of 2 prior tubes placement. Group 1—patients completed pre‐and post‐Eustachian Tube Dysfunction Quality of Life Survey (ETDQ‐7) survey scores, Group 2—patients had available pre‐ and postdilation tympanogram data (TD), and Group 3—patients had both ETDQ‐7 survey and TD. The average time for the first and subsequent follow‐ups was 3.8 and 12.9 months, respectively.ResultsA total of 43 patients (85 ears) underwent BDET. The mean age was 13.3 years (8‐18 years). Twenty‐four patients were male (55.8%) and over 80% were Caucasian. The average mean ETDQ‐7 score before and after dilation was 3.9 and 2.5, respectively. Ninety‐three percent experienced improvement of their postoperative ETDQ‐7 scores and 53% had normal postdilation ETDQ‐7 score (P < .0001). Thirty‐seven ears in Group 2 (60.7%) had improvement in postdilation TD. A greater proportion of ears showed improvement of 62.3% with a 95% confidence interval (CI) [50.1%‐74.5%] compared to 37.7% without improvement, 95% CI [25.5%‐49.87%]. Ears with type A or B TD were more likely to show improvement than ears with type C, perforated, or with tubes (P < .0001). Eighteen out of 30 ears in Group 3 (60%) experienced an improvement in both ETDQ‐7 and tympanogram.ConclusionBDET is a safe, efficacious alternative to tubes in selected pediatric patients.

01 Oct 2024·Science of The Total Environment

Influence of natural organic matter on the aggregation dynamics of biochar colloids derived from various feedstocks

Article

Author: Mao, Meng ; Li, Qirui ; Shang, Jianying ; Chen, Xiuxiu ; Si, Hongyu

Abundant biochar colloids (BCs) produced from a wide range of feedstocks, resulting from forest fires, agricultural production, and environmental restoration, exhibit varying aggregation behaviors influenced by feedstock type and natural organic matter. However, the impact of natural organic matter on the colloidal stability of BCs derived from different feedstocks remains poorly understood. In this study, six selected biochars were derived from various feedstocks as follows: sewage sludge (SS), rice husk (RH), oil seed rape straw pellets (OSR), wheat straw pellets (WS), miscanthus straw pellets (MS) and softwood pellets (SW). The colloidal stability of BCs, with the exogenous addition of organic matter, was further determined. The order of critical coagulation concentrations (CCCs) of BCs with the presence of humic acid (HA) was as follows: RH (989.48 mM) < MS (1084.69 mM) < SS (1149.76 mM) < WS (1338.99 mM) < OSR (2402.98 mM) < SW (3151.32 mM). This order was significantly positively correlated with the specific surface area and negatively correlated with the ash content of the bulk biochar. Compared to HA, bovine serum albumin (BSA) more effectively inhibited the aggregation behavior of BCs due to steric hindrance. The initial aggregation rate constant (k) of BCs at 3000 mM NaCl was as follows: MS (0.238 nm/s) > OSR (0.142 nm/s) > WS (0.128 nm/s) > SS (0.126 nm/s) > RH (0.118 nm/s) > SW (0.112 nm/s). The stabilizing effects of BSA on biochar colloids were independent of the physicochemical properties of bulk biochar. In the presence of BSA, a thin layer of protein corona significantly enhanced the stability of biochar colloids, particularly the BCs derived from MS. Our results underscore the importance of considering feedstock resources and natural organic matter type when assessing the aggregation and potential risks of BCs in aquatic systems.

News (Medical) associated with Emeramide

15 Jul 2023

·www.prnewswire.com

Chronic Obstructive Pulmonary Disease Pipeline Research 2023: Focus on 65+ Companies and 70+ Pipeline Drugs

DUBLIN, July 14, 2023 /PRNewswire/ -- The "Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. With an extensive focus on 65+ companies and 70+ pipeline drugs, this report provides a detailed analysis of the current scenario and growth prospects across the indication. The report encompasses a comprehensive overview of the pipeline drug profiles, covering both clinical and nonclinical stage products. Additionally, it includes a thorough assessment of therapeutics, considering product type, stage, route of administration, and molecule type. Inactive pipeline products in this space are also highlighted, providing a holistic view of the COPD pipeline landscape. To provide a comprehensive understanding, this report outlines the present scenario and growth prospects in the COPD field. It offers detailed insights into the disease overview and treatment guidelines for Chronic Obstructive Pulmonary Disease, setting the stage for a deeper exploration of the pipeline landscape. Furthermore, the report delves into the commercial assessment and clinical assessment of the pipeline products under development. It provides detailed descriptions of each drug, including their mechanisms of action, clinical studies, NDA approvals (if any), and comprehensive product development activities. This encompasses technology, COPD collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant product-related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Chronic Obstructive Pulmonary Disease Emerging Drugs Benralizumab: AstraZeneca Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Dupilumab: Sanofi Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage of development. Tezepelumab: Amgen Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control. Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonary disease. SNG001: Synairgen SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients with COPD. GSK3923868: GlaxoSmithKline GSK3923868, is a PI4kb inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructive pulmonary disease. Chronic Obstructive Pulmonary Disease: Therapeutic Assessment This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Chronic Obstructive Pulmonary Disease There are approx. 65+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca. Phases Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Intramuscular Molecule Type Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Product Type Chronic Obstructive Pulmonary Disease Report Insights Chronic Obstructive Pulmonary Disease Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Key Players Sanofi AstraZeneca Amgen Synairgen GlaxoSmithKline Eisai Meridigen Biotech Chiesi EmeraMed Limited Verona Pharma Tetherex Pharmaceuticals Mereo BioPharma Key Products Lemborexant UMC119-06 CHF5259 Emeramide Ensifentrine SNG001 GSK3923868 Benralizumab Dupilumab Tezepelumab SelK2 BCT197 For more information about this clinical trials report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Phase 2Phase 3ImmunotherapyPhase 1

15 Sep 2022

·www.prnewswire.com

Integrative health podcast and video series Word of Mouth, season two released!

CHAMPIONSGATE, Fla., Sept. 15, 2022 /PRNewswire/ -- The International Academy of Oral Medicine and Toxicology (IAOMT) is raising awareness of the connection between dental conditions and whole body health with season two of its integrative health podcast and video series Word of Mouth. Continue Reading Integrative health podcast and video series Word of Mouth, season two released! Tweet this This unique podcast series focuses on the relationship between oral health and overall health, which is also known as the oral-systemic connection. " This unique podcast series focuses on the relationship between oral health and overall health, which is also known as the oral-systemic connection," explains IAOMT President Dave Edwards, DDS. " All too often, dentistry is excluded from medical care, resulting in a disconnect between the treatment of the mouth and the rest of the body. This is dangerous because oral health conditions are scientifically associated with a wide range of systemic illnesses." In the first episode of Word of Mouth, IAOMT member and past president, Griffin Cole, DDS, NMD, interviews biochemist Boyd Haley, PhD about Emeramide, a safe and effective heavy metals chelator that is going through the FDA approval process. They discuss the risks for dental patients and dental professionals that are associated with mercury dental fillings and the many detrimental health effects from exposure to mercury. New episodes of Word of Mouth will be released every two weeks to explore other concepts relevant to integrative health. In the second episode, IAOMT member Beth Rosellini, DDS, AIAOMT, interviews Earl Bergersen, DDS a pioneer in pediatric sleep, breathing and airway health. The third episode features IAOMT member and past president, David Kennedy, DDS, interviewing Griffin Cole, DDS, NMD, about the adverse health effects from fluoride exposure. The IAOMT expects Word of Mouth to be a long-running series that will forge a more integrated approach to dental and medical care. " What happens in the mouth impacts the rest of the body and vice-versa," IAOMT President Edwards reiterates. " Patients can clearly benefit from an integrative approach to treating the health of their whole body. Our Word of Mouth series will spread this important message." Episodes of Word of Mouth can be found on the Word of Mouth website, as well as Spotify, Apple iTunes, YouTube and Facebook. The IAOMT is a non-profit organization dedicated to biological dentistry and its mission of protecting public health and the environment since it was founded in 1984. Contact: David Kennedy, DDS, IAOMT Public Relations Chair, [email protected] International Academy of Oral Medicine and Toxicology (IAOMT) Phone: (863) 420-6373; Website: SOURCE International Academy of Oral Medicine and Toxicology

100 Deals associated with Emeramide

External Link

KEGG	Wiki	ATC	Drug Bank
-	Emeramide	-	DB12192

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mercury Poisoning	Phase 3	CO	EmeraMed Ltd.	01 Mar 2021
Beta-Thalassemia	Phase 3	AL	EmeraMed Ltd.	21 Nov 2019
Multiple System Atrophy (MSA) With Orthostatic Hypotension	Phase 3	SI	EmeraMed Ltd.	16 Sep 2019
Supranuclear Palsy, Progressive	Phase 3	SI	EmeraMed Ltd.	16 Sep 2019
Pulmonary Disease, Chronic Obstructive	Phase 3	SE	EmeraMed Ltd.	17 Jun 2016
Heavy Metal Poisoning	Phase 3	EC	EmeraMed Ltd.	07 Aug 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02486289 (Pubmed \| Environ Health) Manual	Phase 2	Mercury Poisoning	36	NBMI	(objnenopyy) = Physical fatigue was significantly decreased in the 300 mg NBMI group compared to the control. mrditoedfb (mbcoggdvti ) View more	Positive	14 Feb 2018
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis